HC Wainwright Forecasts Reduced Earnings for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Equities research analysts at HC Wainwright decreased their FY2026 earnings per share estimates for Zenas BioPharma in a research report issued to clients and investors on Monday, November 9th. HC Wainwright analyst M. Caufield now expects that the company will post earnings of ($6.26) per share for the year, down from their prior estimate of ($5.83). HC Wainwright currently has a “Buy” rating and a $44.00 price target on the stock. The consensus estimate for Zenas BioPharma’s current full-year earnings is ($6.09) per share. HC Wainwright also issued estimates for Zenas BioPharma’s Q4 2026 earnings at ($1.39) EPS, FY2027 earnings at ($5.10) EPS, FY2028 earnings at ($3.41) EPS, FY2029 earnings at ($2.42) EPS and FY2030 earnings at ($1.10) EPS.

Several other brokerages have also commented on ZBIO. Weiss Ratings lowered Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Citigroup reiterated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, October 28th. Wedbush reiterated an “outperform” rating and set a $45.00 target price on shares of Zenas BioPharma in a report on Wednesday, September 30th. Morgan Stanley assumed coverage on shares of Zenas BioPharma in a report on Tuesday, October 20th. They issued an “equal weight” rating and a $32.00 price target for the company. Finally, Guggenheim restated a “buy” rating and issued a $55.00 price target on shares of Zenas BioPharma in a report on Wednesday, September 30th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Zenas BioPharma presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Zenas BioPharma Price Performance

Shares of ZBIO stock opened at $28.58 on Wednesday. Zenas BioPharma has a twelve month low of $13.50 and a twelve month high of $44.60. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -3.03 and a beta of -0.88. The stock has a fifty day simple moving average of $28.85 and a two-hundred day simple moving average of $25.22. The company has a current ratio of 9.42, a quick ratio of 9.93 and a debt-to-equity ratio of 1.88.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings data on Thursday, November 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.41). The business had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.00 million.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its stake in Zenas BioPharma by 3.6% in the third quarter. Russell Investments Group Ltd. now owns 13,193 shares of the company’s stock valued at $356,000 after purchasing an additional 453 shares during the last quarter. Candriam S.C.A. bought a new position in Zenas BioPharma in the third quarter worth about $17,725,000. Alps Advisors Inc. lifted its position in shares of Zenas BioPharma by 35.6% during the third quarter. Alps Advisors Inc. now owns 86,369 shares of the company’s stock valued at $2,329,000 after buying an additional 22,694 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zenas BioPharma during the third quarter valued at about $90,000. Finally, Sterling Capital Management LLC boosted its holdings in shares of Zenas BioPharma by 1,090.0% in the 3rd quarter. Sterling Capital Management LLC now owns 1,190 shares of the company’s stock valued at $32,000 after buying an additional 1,090 shares in the last quarter.

Zenas BioPharma Company Profile

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business. Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and Fc?RIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.